US2018236261A1PendingUtilityA1
Method of treatment of eyelid laxity
Assignee: QUEENSLAND EYE INST FOUNDATIONPriority: Feb 21, 2017Filed: Feb 20, 2018Published: Aug 23, 2018
Est. expiryFeb 21, 2037(~10.6 yrs left)· nominal 20-yr term from priority
A61N 5/062A61N 2005/0661A61N 5/0616A61N 5/1017
32
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of treating eyelid laxity in a subject comprising exposing a tarsal plate of an eye, and applying to at least part of the exposed tarsal plate a photosensitizer that initiates crosslinking in response to photo-activating radiation; and irradiating the exposed tarsal plate with photo-activating radiation to initiate crosslinking in the tarsal plate tissue.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating eyelid laxity in a subject comprising:
exposing a tarsal plate of an eye; applying to at least part of the exposed tarsal plate a photosensitizer that initiates crosslinking in response to photo-activating radiation; and irradiating the exposed tarsal plate with photo-activating radiation to initiate crosslinking in the tarsal plate tissue.
2 . The method according to claim 1 wherein the photosensitizer is in solubilized form.
3 . The method according to claim 1 wherein the photosensitizer is riboflavin or a pharmaceutically acceptable salt, derivative or solvate thereof.
4 . The method according to claim 1 wherein the photosensitizer is riboflavin 5′-phosphate or a pharmaceutically acceptable salt or solvate thereof.
5 . The method according to claim 1 wherein the photo-activating radiation is UV-A radiation.
6 . The method according to claim 1 wherein the method comprises:
exposing a tarsal plate of an eye by making an incision;
applying to at least part of the exposed tarsal plate riboflavin or a pharmaceutically acceptable salt, derivative or solvate thereof in solubilized form;
irradiating the exposed tarsal plate with UV-A radiation to initiate crosslinking in the tarsal plate tissue; and
closing the incision.
7 . The method according to claim 1 wherein the method further includes delivery of O 2 gas at a site of irradiation.
8 . The method according to claim 1 performed either simultaneously or sequentially in combination with an additional tightening procedure.
9 . A system configured to crosslink tarsal plate tissue comprising:
an applicator configured to apply a photosensitizer solution to an exposed tarsal plate of an eye; and a radiation source configured to provide photo-activating radiation to the tarsal plate wherein the radiation source provides a beam profile of greater than 12 mm at 10 mm from a surface of the tarsal plate.
10 . The system of claim 9 further comprising a means for delivering O 2 to the tarsal plate.
11 . A method of crosslinking tarsal plate tissue comprising topical application to the tarsal plate of a photosensitizer that initiates crosslinking in response to photo-activating radiation and, simultaneously or subsequently, treating the tarsal plate with photo-activating radiation.
12 . The method according to claim 11 , wherein the photosensitizer is a pharmaceutical composition comprising riboflavin or a pharmaceutically acceptable derivative, salt or solvate thereof.
13 . The method according to claim 12 , wherein the pharmaceutical composition comprises an aqueous solution of riboflavin 5′-phosphate or a pharmaceutically acceptable salt or solvate thereof.
14 . The method according to claim 11 , wherein the radiation is UV-A radiation.
15 . A kit for performing the method of claim 1 comprising a pharmaceutical composition comprising a photosensitizer that initiates crosslinking in response to photo-activating radiation together with an applicator adapted to apply the photosensitizer to a tarsal plate.
16 . A kit according to claim 15 wherein the photosensitizer is riboflavin or a pharmaceutically acceptable salt, derivative or solvate thereof.
17 . A kit according to claim 16 wherein the riboflavin pharmaceutical composition is an aqueous solution.Join the waitlist — get patent alerts
Track US2018236261A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.